November 24th, 2009
Podcast 67: Unexpected “incidental” findings on pulmonary CT angiography present problems of pursuit and follow-up.
Podcast: Play in new window | Download
Subscribe: RSS
This week’s Archives of Internal Medicine investigates what happens when you analyze the outcome of all those pulmonary angiographic CTs ordered in the emergency department to rule out pulmonary embolism.
We talk things over with Dr. Shannon Carson and Dr. William Hall, two of the paper’s principal authors.
It’s Thanksgiving Week here in the U.S., and so there won’t be a news section in this edition. I’ll catch you up next week on what’s happened.
I hope your holiday is pleasant, if you get one, and your workload reasonable, if you don’t.
Interview link:
November 22nd, 2009
Podcast 66: Niacin versus ezetimibe in the face of high cardiovascular risk — a conversation with the ARBITER 6-HALTS trialist Allen Taylor
Podcast: Play in new window | Download
Subscribe: RSS
One of the more intriguing pieces of research presented at the American Heart Association this week (and simultaneously released online in the New England Journal of Medicine) shows that extended-release niacin outperforms ezetimibe in high-risk patients. We talk with Dr. Allen J. Taylor, the study’s first author.
Contact us at 1-617-440-4374 or write jelia@jwatch.org.
This edition’s links:
Interview Link:
News Links:
November 13th, 2009
Podcast 65: A conversation about the utility of renovascular angioplasty in the face of atherosclerosis
Podcast: Play in new window | Download
Subscribe: RSS
Investigators have suspected that there isn’t much advantage to renovascular angioplasty and stenting in atherosclerosis, but their studies haven’t had the statistical power to prove that point. A new bit of research in this week’s New England Journal of Medicine may have hit the mark. We’ve got an interview with two of the principals of the ASTRAL study (that’s their acronym for Angioplasty and Stenting for Renal Artery Lesions). Dr. Philip Kalra, the nephrology lead, and Dr. Jonathan Moss, the radiology lead, kindly agreed to the conversation, which I think you’ll find of interest.
Reach us with your comments and suggestions at jelia@jwatch.org, or call 1-617-440-4374.
This edition’s links:
Interview link–
News links–
November 12th, 2009
Podcast 64: A conversation regarding on-pump versus off-pump CABG with Frederick Grover.
Podcast: Play in new window | Download
Subscribe: RSS
Avoiding use of the heart-lung machine during coronary artery bypass grafting was supposed to lower neurocognitive problems and other complications after the procedure. A large randomized trial finds otherwise. We’ve got a conversation with one of the investigators, Frederick Grover.
To contact us, call 1-617-440-4374. You can write to me at jelia@jwatch.org.
This week’s links:
News links:
- Primary Care Visit Length Increasing
- H1N1 Update: CDC Releases ‘Quick Facts’ for Providers on Antiviral Drug Use
- Aspirin for Primary Prevention ‘Should Not Be Routinely Initiated’
Interview links:
November 2nd, 2009
Podcast 63: A conversation about the adverse cardiometabolic effects of second-generation antipsychotic drugs in young patients with Christoph Correll
Podcast: Play in new window | Download
Subscribe: RSS
There are consequences of even short-term use of some drugs. Take the second-generation antipsychotics. A 3-month course can cause weight gain of almost 20 pounds in young people, according to a JAMA study. We interview Dr. Christoph Correll about the implications.
To reach Clinical Conversations, you can call 1-617-440-4374 or email me at jelia@jwatch.org.
This weeks news and interview links:
News:
Interview:
October 25th, 2009
Podcast 62: A conversation with Jane Kim about cost-effectiveness of vaccinating women with HPV vaccine after age 30.
Podcast: Play in new window | Download
Subscribe: RSS
The FDA seems set to announce a decision about vaccinating women past age 25 for HPV. A paper in the Annals of Internal Medicine this week indicates that such a strategy wouldn’t be cost-effective.
Don’t be put off by “cost-effectiveness” or by the fact that we actually discuss “QALY”s. It’s all good. We’ve got Harvard School of Public Health’s Jane Kim to guide your interviewer through the QALY thicket, and she’s a great guide.
Contact us at 1-617-440-4374 or write to jelia@nejm.org.
This week’s links:
NEWS:
INTERVIEW:
About the Podcast
Comments, suggestions, and story ideas welcome. Learn more about Clinical Conversations.
Follow us:
